Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

21-Aug-2007

Cangene Corporation reported that its contract with the U.S. Centers for Disease Control and Prevention for the supply of Vaccinia Immune Globulin Intravenous (Human) ("VIG") has been extended for five more years. The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered VIG product to the U.S. Strategic National Stockpile ("SNS"). Although a supply of product is already maintained within the SNS, the extended contract supports licensing requirements, ongoing stability studies, further clinical testing and development projects, and could provide for future orders.

VIG is a hyperimmune product to be used in treating and preventing certain types of severe complications that may be associated with smallpox vaccination, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified, specialty antibodies made from plasma.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous